ImmunityBio (IBRX): Analyst Consensus Points to +85% Upside Toward $16 Target

Key Takeaways

• The central target of $16 is the arithmetic mean of five verified, current analyst price targets reviewed for this article.
• The latest verified close is $8.63 (October 27, 2026), meaning the target sits about 85% above the current price.
• Individual targets range widely, from $12 to $23, reflecting genuine disagreement about the company's long-term value.
• The strongest supporting factor is the expanded FDA approval of Anktiva in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), which drove several October 2026 target increases.
• The biggest risks are persistent net losses, heavy cash burn, and execution risk in converting approvals into durable revenue growth.
• Explore the ticker's Major News, Today's Price Move, Forecast, and Earnings for additional context on recent developments and forward estimates.
• For broader market insight, explore Trending AI Robots, which scan the market for shifting technical and fundamental patterns.

Analyst Price Targets and Consensus View

The $16 central target reflects five current analyst price targets gathered from sources identifying the analyst, firm, target, and date: BTIG at $12, Jefferies at $14, H.C. Wainwright at $15, Piper Sandler at $16, and D. Boral Capital at $23. The arithmetic mean of these five values is $16.00, which rounds to a clean $16 target. The low-to-high range of $12 to $23 is unusually wide, underscoring how differently analysts weight the company's pipeline optionality.

Views lean bullish—nearly all ratings are Buy or Overweight equivalents—but the magnitude of conviction varies sharply. The most cautious target ($12) emphasizes near-term commercial execution and liquidity, while the most optimistic ($23) assigns meaningful value to Anktiva's expansion into additional bladder-cancer settings and systemic immunotherapy programs. Notably, Piper Sandler raised its target to $16 from $12 and Jefferies to $14 from $12 in mid-October 2026, both citing the FDA's expanded Anktiva approval in BCG-unresponsive NMIBC with papillary-only tumors. H.C. Wainwright reiterated its $15 target the same week. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

At the latest verified close of $8.63, reaching $16 would require an advance of approximately 85%, which qualifies as a very large move rather than a modest or routine one. The stock has already demonstrated substantial momentum, with a 52-week range spanning roughly $1.95 to $12.43, and shares remain well above the prior troughs of early 2026.

The path toward the target would most plausibly run through continued commercial execution of Anktiva, additional label expansions, and progress in later-stage trials. Full-year 2026 revenue is projected to roughly double from 2025 levels—analysts model roughly $226 million in 2026 versus $113 million in 2025—but the company continues to post significant net losses, including a GAAP net loss of about $230 million in the June 2026 quarter.

What Could Support a Move Toward the Target

• Anktiva (nogapendekin alfa inbakicept-pmln), an IL-15 superagonist immunotherapy, is now approved in expanded BCG-unresponsive NMIBC indications, broadening the addressable patient population.
• Revenue is scaling rapidly from a low base, with analysts projecting growth of roughly 100% in 2026.
• A pipeline of additional indications—including earlier-stage bladder cancer and systemic cancers—offers optionality that analysts increasingly reference in their valuations.
• Recent analyst target increases and a predominantly bullish rating posture indicate rising conviction in the commercial ramp.

What Could Prevent the Target From Being Reached

• Sustained operating losses and high cash burn could pressure the balance sheet and require additional financing, diluting shareholders.
• Commercial execution risk remains high: converting expanded approvals into durable, growing sales is not guaranteed.
• The wide analyst range ($12 to $23) signals that the bullish case depends on assumptions about future indication expansion that may not materialize.
• Biotech valuations are sensitive to interest-rate expectations and broad sector rotation, which can compress multiples even when fundamentals improve.

Technical Levels and Market Structure

The stock's 52-week range of roughly $1.95 to $12.43 places the current price in the upper portion of that band. The $12.43 prior high stands out as a meaningful resistance level, while the $12 analyst target roughly coincides with that zone. On the downside, the area near the rising 200-day moving average, recently around $7.82, represents a longer-term support level. Reaching $16 would require first clearing the $12–$13 area and then extending well beyond the stock's prior record territory.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of approximately 12 months, though individual analysts may use different assumptions, and no target should be read as a timing guarantee. Investors should watch the next quarterly earnings report (scheduled for early November 2026), updates on Anktiva's commercial launch, any further FDA or international regulatory decisions, and revisions to analyst targets. Liquidity and financing developments also warrant close attention given the company's cash burn.

Final Assessment

The $16 central target represents the average of five analyst price targets spanning $12 to $23, and it implies a roughly 85% advance from the latest close of $8.63—a very large move. The case for reaching it rests on Anktiva's expanded approval, rapid revenue growth, and a pipeline that analysts increasingly reward with higher targets. The case against it rests on persistent losses, cash burn, execution uncertainty, and the unusually wide dispersion among analyst estimates, which signals that even bullish analysts disagree sharply about value. Investors should focus on quarterly results, commercial trajectory, regulatory catalysts, and any financing announcements, while treating the $16 figure as a calculated mean—not a guarantee.

Using AI Daily Buy/Sell Signals in Practice

In my own workflow, Tickeron's AI Daily Buy/Sell Signals provide a practical layer for monitoring names like IBRX. The tool scans thousands of stocks daily and flags shifts in technical and fundamental conditions, which helps me stay on top of momentum changes without replacing deeper research. It has become a useful complement when evaluating volatile clinical-stage names.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Notable companies

Industry description

Market Cap

High and low price notable news

Volume